STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Transcend Discloses 2.6% IN8bio Stake — 107,416 Shares Reported

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

This Amendment No. 2 to a Schedule 13G discloses that Transcend Partners Opportunity Fund I LLC beneficially owns 107,416 shares of IN8bio common stock, representing 2.6% of the class. The percentage is calculated using 4,078,139 shares outstanding as reported as of June 30, 2025. The Reporting Person reports no sole voting or sole dispositive power and instead reports shared voting and shared dispositive power over the shares. Actions regarding these shares require a majority vote of Transcend's managing members, each of whom disclaims beneficial ownership. The amendment is a disclosure of beneficial ownership rather than an indication of control.

Positive

  • None.

Negative

  • None.

Insights

TL;DR Holding of 107,416 shares (2.6%) is a modest, disclosed stake with shared — not sole — control, a neutral ownership update for investors.

The statement reports a 2.6% beneficial position based on 4,078,139 shares outstanding and specifies that the Reporting Person holds shared voting and dispositive power while reporting no sole powers. For investors, the size of the stake is below 5% and the governance mechanics restrict unilateral action, making this a compliance disclosure with limited immediate market impact.

TL;DR Shared control through managing members and disclaimers suggests the position does not signal a control attempt and has limited governance influence.

The filing clarifies that voting and disposition require a majority of Transcend's managing members and that those managers disclaim beneficial ownership. This structure indicates internal allocation of decision rights within the Reporting Person rather than direct, individual control. As an amendment to a Schedule 13G, the disclosure enhances transparency about who holds collective authority but does not, by itself, evidence a change in issuer control.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G



Transcend Partners Opportunity Fund LLC
Signature:/s/ Nina Fairbairn
Name/Title:Nina Fairbairn, Managing Member
Date:08/13/2025
In8Bio, Inc.

NASDAQ:INAB

INAB Rankings

INAB Latest News

INAB Latest SEC Filings

INAB Stock Data

8.43M
4.38M
5.56%
19.29%
1.01%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
NEW YORK